next chance

Prima Biomed // Sym:Prr

“Prima has demonstrated early,
interim efficacy for CVacTM which
suggests the vaccine may prove
effective in end-stage patients.
We await the full set of results
in 1Q 2007 but believe that at a
market cap of $10million and the
possibility of a near term license deal,
Prima is one stock to watch in the
therapeutic vaccine space” Dr Thomas
Duthy, Biotechnology Equities
Analyst, Taylor Collison.